Sino Biopharmaceutical Limited
SBMFF
$0.9891
$0.03914.12%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 903.03M | 907.39M | 1.10B | 1.11B | 825.16M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 903.03M | 907.39M | 1.10B | 1.11B | 825.16M |
| Cost of Revenue | 173.17M | 174.01M | 196.42M | 198.12M | -- |
| Gross Profit | 729.85M | 733.38M | 899.64M | 907.44M | -- |
| SG&A Expenses | 369.19M | 370.98M | 472.82M | 476.92M | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 242.56M | 243.74M | 187.25M | 188.87M | -- |
| Total Operating Expenses | 784.93M | 788.73M | 856.49M | 863.91M | 658.91M |
| Operating Income | 118.10M | 118.67M | 239.57M | 241.65M | 166.25M |
| Income Before Tax | 115.62M | 116.18M | 249.53M | 251.70M | -- |
| Income Tax Expenses | -8.42M | -8.46M | 42.40M | 42.77M | -- |
| Earnings from Continuing Operations | 124.05M | 124.65M | 207.13M | 208.93M | -- |
| Earnings from Discontinued Operations | -1.85M | -1.86M | 110.94M | 111.90M | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -88.64M | -89.07M | -109.75M | -110.70M | -- |
| Net Income | 33.55M | 33.71M | 208.32M | 210.13M | 74.32M |
| EBIT | 118.10M | 118.67M | 239.57M | 241.65M | 166.25M |
| EBITDA | 150.76M | 152.28M | 272.80M | 275.16M | -- |
| EPS Basic | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| EPS Diluted | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Average Basic Shares Outstanding | 18.18B | 18.18B | 18.41B | 18.41B | 18.53B |
| Average Diluted Shares Outstanding | 18.18B | 18.18B | 18.41B | 18.41B | 18.53B |
| Dividend Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payout Ratio | -- | -- | -- | -- | 27.13% |